4.5 Review

Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review

Journal

DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 148, Issue -, Pages 54-63

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2018.11.016

Keywords

Diabetes mellitus; Advanced glycation end products; AGE cross-link breaker; AGE inhibitors; RAGE antagonists

Ask authors/readers for more resources

Diabetes mellitus (DM) defines metabolic disorders, characterised by elevated levels of blood glucose. Chronic hyperglycaemic state promotes consequently the formation of advanced glycation end products (AGEs) and the expression of their receptor (RAGE) which aggravate many diabetic complications. Due to the relevant role of AGEs and RAGE, several therapeutic approaches with an anti-AGE or RAGE-antagonizing effect are investigated. These therapeutic options include AGE cross-link breakers, AGE inhibitors, RAGE antagonists, drugs clinically approved for various indications like antidiabetic, antihypertensive drugs or statins, as well as dietary and phytotherapeutic approaches. The aim of this review is to give an overview of these therapeutic approaches, their outcomes in clinical studies and their role in the management of diabetes and its complications. (C) 2018 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available